Profound Medical (PROF) entered into a definitive co-sales and co-marketing agreement with Siemens Healthineers (SIEGY) pursuant to which the companies will commercialize a new MRI-guided prostate therapy solution which combines Profound’s TULSA-PRO system and consumables with Siemens Healthineers’ Magnetom Free.Max magnetic resonance scanner. Subject to the completion of the compatibility process of TULSA-PRO and Magnetom Free.Max, the companies currently expect to initiate sales of the total prostate solution in 2025.

Don't Miss our Black Friday Offers:

• Unlock your investing potential with TipRanks Premium - Now At 40% OFF!

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on PROF:

• Profound Medical Advancements in Prostate Treatment

• Profound Medical to unveil third TULSA-AI module at RSNA 2024

• Profound Medical to Present at Stifel Conference

• Profound Medical reports Q3 EPS (38c), consensus (30c)

• Profound Medical Sees Strong Growth with TULSA-PRO®